Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein
PDF | Full Text | Supplementary Files | How to cite | Press Release | Podcast
Metrics: PDF 1053 views | Full Text 2148 views | ?
Hwudaurw Chen1, Earlphia Sells2, Ritu Pandey1,3, Edward R. Abril1, Chiu-Hsieh Hsu4, Robert S. Krouse5,6, Raymond B. Nagle7, Georgios Pampalakis8, Georgia Sotiropoulou8 and Natalia A. Ignatenko1,3
1 University of Arizona Cancer Center, Tucson, AZ, USA
2 Biochemistry and Molecular and Cellular Biology Graduate Program, Department of Molecular and Cellular Biology, College of Science, University of Arizona, Tucson, AZ, USA
3 Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA
4 Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
5 University of Arizona College of Medicine, Tucson, AZ, USA
6 Southern Arizona Veterans Affairs Health Care System, Tucson, AZ, USA
7 Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ, USA
8 Department of Pharmacy, University of Patras, Patras, Greece
|Natalia A. Ignatenko,||email:||[email protected]|
Keywords: colorectal cancer; kallikrein-related peptidase 6 or KLK6; SMAD2/3; epithelial-mesenchymal transition; HMGA2
Received: February 15, 2018 Accepted: July 30, 2019 Published: October 22, 2019
Kallikrein-related peptidase 6 (KLK6) overexpression is commonly observed in primary tumors of colorectal cancer (CRC) patients and has been associated with tumor aggressiveness, metastasis, and poor prognosis. We previously established a unique contribution of KLK6 in colon cancer metastasis via a specific network of microRNAs and mRNAs. Here we evaluated the cellular functions of KLK6 protease in Caco-2 colon adenocarcinoma cell line after introduction of the enzymatically active or inactive form of the enzyme. We found that proteolytically active KLK6 increased Caco-2 cells invasiveness in vitro and decreased the animal survival in the orthotopic colon cancer model. The active KLK6 induced phosphorylation of SMAD 2/3 proteins leading to the altered expression of the epithelial-mesenchymal transition (EMT) markers. KLK6 overexpression also induced the RNA-binding protein LIN28B and high-mobility group AT-hook 2 (HMGA2) transcription factor, two essential regulators of cell invasion and metastasis. In the CRC patients, KLK6 protein levels were elevated in the non-cancerous distant and adjacent tissues, compared to their paired tumor tissues (p < 0.0001 and p = 0.0157, respectively). Patients with mutant K-RAS tumors had significantly higher level of KLK6 protein in the luminal surface of non-cancerous distant tissue, compared to the corresponding tissues of the patients with K-RAS wild type tumors (p ≤ 0.05). Furthermore, KLK6 and HMGA2 immunohistochemistry (IHC) scores in patients’ tumors and paired adjacent tissues positively correlated (Spearman correlation P < 0.01 and p = 0.03, respectively). These findings demonstrate the critical function of the KLK6 enzyme in colon cancer progression and its contribution to the signaling network in colon cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.